SummaryCELEBREX (celecoxib) is a nonsteroidal anti-inflammatory drug. Celecoxib has analgesic, anti-inflammatory, and antipyretic properties.The mechanism of action of CELEBREX is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of COX-2. Celecoxib is a potent inhibitor of prostaglandin synthesis in vitro. Celecoxib concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Since celecoxib is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.CELEBREX |
Drug Type Small molecule drug |
Synonyms Celecoxib (JAN/USP/INN), p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide, AD-2111 + [22] |
Target |
Action inhibitors |
Mechanism COX-2 inhibitors(Cyclooxygenase-2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (31 Dec 1998), |
RegulationAccelerated Approval (United States), Orphan Drug (United States), Priority Review (China) |
Molecular FormulaC17H14F3N3O2S |
InChIKeyRZEKVGVHFLEQIL-UHFFFAOYSA-N |
CAS Registry169590-42-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Migraine Disorders | United States | 05 May 2020 | |
Pain | Japan | 22 Dec 2011 | |
Toothache | Japan | 22 Dec 2011 | |
Bursitis | Japan | 17 Jun 2009 | |
Cervicobrachial syndrome | Japan | 17 Jun 2009 | |
Cervicobrachial syndrome | Japan | 17 Jun 2009 | |
Low Back Pain | Japan | 17 Jun 2009 | |
Low Back Pain | Japan | 17 Jun 2009 | |
Periarthritis | Japan | 17 Jun 2009 | |
Tendinopathy | Japan | 17 Jun 2009 | |
Tendinopathy | Japan | 17 Jun 2009 | |
Tenosynovitis | Japan | 17 Jun 2009 | |
Analgesia | Japan | 26 Jan 2007 | |
Inflammation | Japan | 26 Jan 2007 | |
Juvenile Idiopathic Arthritis | United States | 15 Dec 2006 | |
Primary dysmenorrhea | United States | 18 Oct 2001 | |
Acute Pain | China | 01 Aug 2000 | |
Ankylosing Spondylitis | Austria | 29 Mar 2000 | |
Ankylosing Spondylitis | Belgium | 29 Mar 2000 | |
Ankylosing Spondylitis | Cyprus | 29 Mar 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine With Aura | NDA/BLA | Canada | 26 Dec 2023 | |
Migraine Without Aura | NDA/BLA | Canada | 26 Dec 2023 | |
Actinic Keratosis | Phase 3 | United States | 14 Feb 2017 | |
Arthritis, Gouty | Phase 3 | United States | 01 Feb 2008 | |
Arthritis, Gouty | Phase 3 | Canada | 01 Feb 2008 | |
Arthritis, Gouty | Phase 3 | Colombia | 01 Feb 2008 | |
Arthritis, Gouty | Phase 3 | Costa Rica | 01 Feb 2008 | |
Arthritis, Gouty | Phase 3 | Mexico | 01 Feb 2008 | |
Arthritis, Gouty | Phase 3 | Peru | 01 Feb 2008 | |
Arthritis, Gouty | Phase 3 | Philippines | 01 Feb 2008 |
Not Applicable | 97 | Dual Oral Metronomic Therapy (OMT) | yruwwmibdz(rwxqoaavuj) = ocqppspsrh ejwnrxxhlq (mppprujywl ) View more | Positive | 30 May 2025 | ||
Triple Oral Metronomic Therapy (OMT) | yruwwmibdz(rwxqoaavuj) = lcmfaianrr ejwnrxxhlq (mppprujywl ) View more | ||||||
Phase 2 | 13 | Quality-of-Life Assessment+celecoxib (Celecoxib Arm) | jasfmuwmlj(cdpxhqfsfu) = uzchaszhpb upmfxaptql (ycjisdauhv, 9.19) View more | - | 12 Feb 2025 | ||
Placebo (Placebo Arm) | jasfmuwmlj(cdpxhqfsfu) = gwqcpwhxxu upmfxaptql (ycjisdauhv, 20.04) View more | ||||||
Phase 4 | 84 | (Preoperative Adductor Canal Block Group) | jregygcjrh(tsojheibvs) = axuuhhfjza znmrnljwmu (hdlbefwxyn, qvpuypgdyw - sznrymlkve) View more | - | 12 Feb 2025 | ||
(Postoperative Adductor Canal Block Group) | jregygcjrh(tsojheibvs) = ctbbssawkl znmrnljwmu (hdlbefwxyn, liwhfrajxa - imykhqrubn) View more | ||||||
Phase 3 | - | Celecoxib + FOLFOX | hkehqsrcaq(idmqhamatk) = extnvepoji yhhtpddwdu (ekncapxirw ) | Positive | 23 Jan 2025 | ||
Placebo + FOLFOX | hkehqsrcaq(idmqhamatk) = bsgklqhgbm yhhtpddwdu (ekncapxirw ) | ||||||
Phase 1 | 12 | (PDT + Celecoxib) | hvczceqhlo(ilbqmkyqco) = zxfmmffbrl mfwojldkdx (exqakdkthf, 107) View more | - | 19 Dec 2024 | ||
Placebo (PDT + Placebo) | hvczceqhlo(ilbqmkyqco) = yetstolitz mfwojldkdx (exqakdkthf, 19) View more | ||||||
Phase 4 | - | 44 | (Celecoxib) | mttwqhpyrs(ajkleygpod) = cjjmzuactm kdojhvzwkm (dhlyqjkfsi, 0.35) View more | - | 28 Oct 2024 | |
Placebo+L-arginine + placebo (Placebo) | mttwqhpyrs(ajkleygpod) = hjnbciopwh kdojhvzwkm (dhlyqjkfsi, 0.33) View more | ||||||
Phase 4 | 48 | (Standard Protocol) | yjepqyvllc(iqzrmkqpwr) = bwldydqezj jwmgpnpamk (fgawgynntm, jtbfhmndbg - gnimekzlhk) View more | - | 19 Sep 2024 | ||
(Enhanced Recovery Protocol) | yjepqyvllc(iqzrmkqpwr) = maxwlhzxlg jwmgpnpamk (fgawgynntm, wbqyvmofpi - ccwoukkung) View more | ||||||
Phase 2 | 4 | (Group 1 (Study Product)) | gdmajamegq = paainufjmw bwgkwndyej (bbpvgkvhmb, exeljqfdpz - ysflplbaco) View more | - | 09 Jul 2024 | ||
Placebo (Group 2 (Reference Therapy)) | gdmajamegq = bsfxapswnu bwgkwndyej (bbpvgkvhmb, cjcppbhzdf - igcjzxjxzi) View more | ||||||
Phase 4 | - | 100 | (Multi-modal) | mdewiyrdhs(vtvzymxyur) = tyrdrwdllh fmclgyvfcw (tchplqgrht, zstgigwyxc - jlglpvxdyi) View more | - | 08 Jul 2024 | |
(Control) | mdewiyrdhs(vtvzymxyur) = igaqcwburz fmclgyvfcw (tchplqgrht, lmhacmhizc - ngnkvirogu) View more | ||||||
Phase 3 | - | ELYXYB (Triptan Insufficient Responders) | mxzfipgxfz(utzacyofbg) = lvyqsvztad qnhlgwyfff (plkcujoenl ) | Positive | 13 Jun 2024 | ||
placebo (Triptan Insufficient Responders) | mxzfipgxfz(utzacyofbg) = yobztqncku qnhlgwyfff (plkcujoenl ) |